Literature DB >> 15727498

Opioid craving and seeking behavior in physically dependent volunteers: effects of acute withdrawal and drug reinforcement opportunity.

Mark K Greenwald1.   

Abstract

This study examined whether acute opioid withdrawal and drug reinforcement opportunity increase opioid craving and seeking behavior. The author used a 3 x 2 within-subject randomized crossover design to assess craving and operant behavioral effects of 3 pretreatments (naloxone 0.1 mg/70 kg, fentanyl 0.75 mg/70 kg, or saline iv) and drug or money reinforcement opportunity in 8 methadone-maintained volunteers. Each pretreatment was paired with response-contingent (15 x fixed-ratio 100) delivery of drug (fentanyl 1.5 mg/70 kg iv) and money (rated equivalent of fentanyl) in different sessions. Naloxone significantly increased opioid craving, withdrawal signs, and symptoms, but not operant behavior, relative to saline and fentanyl pretreatment. However, drug versus money reinforcement opportunity did not significantly increase opioid craving or seeking behavior.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15727498     DOI: 10.1037/1064-1297.13.1.3

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  3 in total

1.  Yohimbine increases opioid-seeking behavior in heroin-dependent, buprenorphine-maintained individuals.

Authors:  Mark K Greenwald; Leslie H Lundahl; Caren L Steinmiller
Journal:  Psychopharmacology (Berl)       Date:  2012-11-17       Impact factor: 4.530

2.  Behavioral economic analysis of drug preference using multiple choice procedure data.

Authors:  Mark K Greenwald
Journal:  Drug Alcohol Depend       Date:  2007-10-18       Impact factor: 4.492

3.  Does report of craving opioid medication predict aberrant drug behavior among chronic pain patients?

Authors:  Ajay D Wasan; Stephen F Butler; Simon H Budman; Kathrine Fernandez; Roger D Weiss; Shelly F Greenfield; Robert N Jamison
Journal:  Clin J Pain       Date:  2009 Mar-Apr       Impact factor: 3.442

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.